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l-Opioid Receptor Is Induced by IL-13 within Lymph
Nodes from Patients with Se´zary Syndrome
Alan Be´nard1,2, Pierre Cavaille`s1, Je´roˆme Boue´1,2, Emmanuelle Chapey1,2, Jagadeesh Bayry3,4,5,
Catherine Blanpied1,2, Nicolas Meyer6, Laurence Lamant1,2, Srini V. Kaveri3,4,5, Pierre Brousset1,2 and
Gilles Dietrich1,2
Endogenous opioid peptides mainly produced by neurons are also released by immune cells. They bind to
m- (m-opioid receptor, MOR), d-, and k-opioid receptors. On the basis of studies on mice showing that MOR is
the main mediator of the deleterious effects of opioids on immunity, we wondered whether MOR, absent under
normal conditions, is expressed in some pathological situations such as lymphomas. mRNA expression for all
three opioid receptors was examined in lymph node biopsy samples from patients with non-Hodgkin’s B-cell
and T-cell lymphomas. We found that MOR and one of its ligands (enkephalin) are simultaneously expressed
almost exclusively in lymph nodes from patients with Se´zary cutaneous T cell lymphoma. As MOR was
undetectable in circulating malignant T lymphocytes and in normal immune cells, we hypothesized that tumor-
released cytokines might induce MOR expression in non-neoplastic lymph node cells. The correlation between
mRNA levels of MOR and interleukin-13 (IL-13) within lymph nodes from Se´zary patients led us to investigate
the ability of IL-13 to upregulate MOR expression in normal immune cell subsets. We found that IL-13
upregulates MOR in activated Langerhans cells. Thus, our data suggest that, under pathological conditions, IL-13
overexpression might allow immune-derived endogenous opioids to down-modulate immune response.
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INTRODUCTION
Endogenous opioid peptides belong to three families:
endorphins, enkephalins, and dynorphins, which are derived
from protein precursors encoded by three distinct genes: the
proopiomelanocortin, the proenkephalin, and the prodynor-
phin genes, respectively. The biological activities of the
opioid neuropeptides are mediated by three types of seven-
pass transmembrane segment G-protein-coupled receptors
named m- (MOR), d- (DOR), and k- (KOR) opioid receptors.
b-Endorphin and enkephalins bind to both MOR and DOR,
whereas dynorphin interacts only with KOR. The opioid
system including endogenous opioid neuropeptides and their
receptors are involved in several key neurophysiological
functions, such as analgesia, regulation of autonomic nervous
system and neuroendocrine activities, itching, respiration,
and gastrointestinal motility. Studies focusing on the ther-
apeutic use of exogenous opioid drugs or the release of
endogenous opioids under stressful situations indicated that
opioids also affect innate and adaptive immune responses.
The link between opioids and immune system is strengthened
by the observation that both immune cells and neurons
express opioid receptors and have the ability to synthesize
endogenous opioid peptides (Labuz et al., 2009).
mRNA encoding opioid receptors have been found in
immune cells including T and B lymphocytes, macrophages,
and dendritic cells (DCs). The expression level of all three
opioid receptor subclasses is not homogeneous among cell
subsets and may differ according to the local environment
and the activation status. Thus, DOR mRNA is expressed at
a low level in immature DCs and is virtually absent in resting
T lymphocytes. However, upon activation of the cells, the
expression of DOR is upregulated (Nguyen and Miller,
2002; Jaume et al., 2007; Benard et al., 2008). The MOR
mRNA undetectable in resting T lymphocytes and found
in some activating conditions, is upregulated within an
interleukin (IL)-4- or tumor necrosis factor-alpha-rich micro-
environment (Gave´riaux et al., 1995; Kraus et al., 2001,
2003a, b; Madden et al., 2001; Jaume et al., 2007; Borner
et al., 2008). It is noteworthy that most of the immunosup-
pressive effects of morphine or stress-induced endogenous
opioid release, such as apoptosis of spleen cells, reduction
of both inflammation and natural killer cell activity, are
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mediated through MOR activation in mice (Shavit et al.,
1984; Gave´riaux-Ruff et al., 1998; Yin et al., 1999, 2000;
Mace et al., 2002; Wang et al., 2002a, b; Philippe et al.,
2003). As a matter of fact, although DOR and enkephalins
are together expressed in both CD4þ T lymphocytes
and antigen-presenting mature DCs, opioid receptor neutra-
lization altered neither the antigen-induced proliferation of
lymphocytes nor their sensitivity to apoptosis in vivo (Jaume
et al., 2007).
Considering that MOR is the main mediator of the
deleterious effects of opioids on immunity, we wondered
whether MOR, which is absent in normal lymph node cells
but can be induced by cytokines, is expressed in some
pathological situations such as lymphomas. The expression
of mRNA encoding for all three opioid receptor classes
was examined in a number of lymph node biopsy samples
originating from tumor-free patients or from patients with
non-Hodgkin’s B-cell or T-cell lymphomas. We found that
MOR, together with the enkephalin precursor (proenkephalin,
PENK), is almost exclusively expressed in lymph nodes
from patients with Se´zary cutaneous T-cell lymphoma. As
both circulating Se´zary tumor cells and normal lymph node
cells do not express MOR, we hypothesized that tumor-
related cytokines might induce MOR expression in surround-
ing normal immune cells. Our results showed a correlation
between mRNA levels of MOR and IL-13 within lymph nodes
from Se´zary patients. We then investigated the ability of IL-13
to upregulate MOR expression in normal immune cells,
including T lymphocytes, monocytes, monocyte-derived
conventional DCs or Langerhans cells (LCs). Our results
show that MOR is induced by IL-13 in activated LCs, the
predominant antigen-presenting cells within lymph nodes
draining inflamed skin. On the basis of the MOR-mediated
immunosuppressive effects of opioids, our observations
provide a new potential opioid-dependent tumor escape
mechanism.
RESULTS
MOR is recurrently expressed in lymph node biopsy samples
from patients with Se´zary cutaneous T-cell lymphoma
Expression of mRNA encoding for PENK and all three opioid
receptor subclasses: MOR, DOR, and KOR was investigated
by RT–PCR in a variety of lymph node biopsy samples from
patients with B-cell and T-cell non-Hodgkin’s lymphomas. As
shown in Figure 1, the expression of mRNA encoding DOR
and KOR was not restricted to a particular group of
lymphomas. By contrast MOR mRNA was almost exclusively
found in lymph node biopsies from patients with Se´zary
syndrome. In addition, although DOR and KOR were
expressed in about 40% of normal reactive lymph nodes,
MOR was not found in physiological conditions (Figure 1).
The PENK mRNA was expressed in all lymph node speci-
mens, including tumor-free specimens and lymphoma biopsy
samples (Figure 1). Sequence analysis of PCR products
revealed 100% identity with the corresponding referential
complementary DNA sequences (data not shown).
Histiocytes, within lymph nodes from patients with Se´zary
syndrome, commonly exhibit ceroid deposits accountable for
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Figure 1. Opioid receptor expression in lymph node biopsies from patients
with non-Hodgkin’s B- and T-cell lymphomas. Expression of mRNA
encoding for all three opioid receptor classes, MOR, DOR, and KOR,
was examined by RT–PCR using the human neuroblastoma cell lines SH-SY5Y
and SK-N-MC as controls. cDNA was synthesized from total RNA extracted
from tumor-free RLN samples (hatched bars, n¼ 9) and lymph node biopsy
samples originating from patients with either non-Hodgkin’s B-cell
lymphomas (open bars), including DLCL (n¼ 11) and FL (n¼ 8), or
non-Hodgkin’s T-cell lymphomas (closed bars), including PTCL (n¼ 8), SS
(n¼5), and ALCL (n¼ 7). RT–PCR experiments were performed twice from
total RNA extracted from two independent sets of 20 50-mm-thick frozen
sections. Results are expressed as percentage of opioid receptor-expressing
biopsies. ALCL, anaplastic large cell lymphoma; cDNA, complementary
DNA; DLCL, diffuse large cell lymphoma; DOR, d-opioid receptor;
FL, follicular lymphoma; KOR; k-opioid receptor; MOR, m-opioid
receptor; PTCL, peripheral T-cell lymphoma; RLN, reactive lymph node;
SS, Se´zary syndrome.
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non-specific binding of rabbit IgG. This irrelevant IgG
binding excluded the use of commercial polyclonal anti-
MOR rabbit antibodies to directly stain MOR-expressing
cells in situ. Thus, to determine whether MOR expression
within lymph nodes from Se´zary syndrome patients was due
to tumor cells, we took advantage that Se´zary syndrome
represents the leukemic form of peripheral cutaneous T-cell
lymphoma with the presence of large amounts of tumor cells
into the blood. The expression of MOR in Se´zary tumor cells
was investigated by RT–PCR in peripheral blood mono-
nuclear cells containing up to 78% of Se´zary cells. The
expression of MOR mRNA was never found in peripheral
blood leukocytes with a high tumor Se´zary cell involvement,
as assessed by morphological analysis of blood smears and
amplification of CD158k complementary DNA (Ortonne
et al., 2006; Table 1).
MOR expression is correlated with that of IL-13 within lymph
nodes from patients with Se´zary syndrome
The absence of MOR in Se´zary tumor cells and lymph node
cells under normal conditions (i.e. normal tumor-free reactive
lymph nodes) led us to conjecture a key role for the lymph
node microenvironment in the acquisition of MOR in Se´zary
syndrome. As Se´zary cells are described as arising from a
clonal expansion of mature T helper lymphocytes exhibiting
a propensity to produce T helper-2 (Th2)-related cytokines
(Dummer et al., 1996), we hypothesized a cytokine-
dependent MOR upregulation mechanism in the lymph node
microenvironment.
mRNA encoding for the prototypical Th2 cytokines: IL-4,
IL-5, IL-10, and IL-13 were quantified by real-time PCR in
lymph node biopsies. The mRNA level in each patient’s
sample was normalized relative to the average of those
measured in normal lymph node biopsies. The levels of
mRNA for IL-4, IL-5, and IL-10 estimated within lymph nodes
from patients with Se´zary syndrome were not significantly
different from those measured in tumor-free individuals or in
patients with other types of non-Hodgkin’s lymphomas
(Figure 2). By contrast, IL-13 mRNA expression was
significantly higher within lymph nodes from patients with
Se´zary syndrome as compared with the other groups of
patients (Po0.001, one-way analysis of variance, followed
by Bonferroni’s multiple comparison test). Furthermore, IL-13
mRNA was significantly overexpressed within MOR-expres-
sing lymph node biopsy samples (including MOR-expressing
follicular B-cell lymphoma patients) when compared with the
Table 1. MOR expression in PBMCs from patients
with Se´zary syndrome1
Patients
Sex/age
(years)
CD3+CD4+
(%)
Se´zary cells
(%) CD158K MOR
M/86 79 26 + 
M/68 ND 21 + 
M/51 95 78 + 
M/39 63 54 + 
M/49 64 27 + 
F/54 ND 67 + 
Abbreviations: CD, cluster of differentiation; MOR, m-opioid receptor;
PBMC, peripheral blood mononuclear cell.
1PBMCs were isolated from blood samples by density centrifugation.
Relative content in CD3+CD4+ was determined by cytofluorometry.
Se´zary cells displaying a cerebriform nucleus and a high nucleus-to-
cytoplasm ratio were identified through examination of smears. Expres-
sion of MOR and CD158k were investigated by RT–PCR.
IL-4
IL-10 IL-13 P < 0.001
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Figure 2. mRNA expression of the Th2-related cytokines in lymph node
biopsies from patients with non-Hodgkin’s lymphomas. mRNA encoding for
IL-4, IL-5, IL-10, and IL-13 were quantified by real-time PCR in tumor-free
RLN (&) and lymph nodes from patients with either non-Hodgkin’s B-cell
lymphomas, including DLCL (n) and FL (J), or non-Hodgkin’s T-cell
lymphomas, including PTCL (K), SS (m), and ALCL (’). mRNA content was
normalized to the metastatic lymph node protein 51 (MLN51) mRNA and
quantified relative to standard cDNA prepared from the Jurkat leukemia T cell
line (calibrator sample). For each sample, mRNA level was expressed relative
to the average of mRNA levels in normal reactive lymph nodes. Gene
expression in each sample was assessed in at least two independent
experiments run in duplicate. Data were analyzed by using a one-way
ANOVA followed by Bonferroni’s multiple comparison test. ALCL, anaplastic
large cell lymphoma; ANOVA, analysis of variance; cDNA, complementary
DNA; DLCL, diffuse large cell lymphoma; DOR, d-opioid receptor;
FL, follicular lymphoma; IL, interleukin; KOR; k-opioid receptor; MOR,
m-opioid receptor; PTCL, peripheral T-cell lymphoma; RLN, reactive lymph
node; SS, Se´zary syndrome.
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MOR-lacking biopsy samples (Po0.0001, unpaired t-test),
(Figure 3a). The IL-13 and MOR mRNA expression levels
were correlated (Po0.01; Spearman correlation test, r¼0.94;
Figure 3b). Thus, our data led us to speculate that MOR could
be induced by IL-13 in lymph node cells from patients with
Se´zary syndrome.
MOR is induced by IL-13 in mature LCs
We focused first on the identification of the potential cellular
targets of IL-13 by examining the surface expression of the
functional IL-13 receptor-a1 chain (IL-13Ra1) on immune
cell subsets including circulating Se´zary tumor cells. The
expression of IL-13Ra1 was investigated in peripheral blood
mononuclear cell gated on CD3CD14þ monocytes and
CD3þCD4þ T lymphocytes from both healthy individuals
and Se´zary syndrome patients. As expected, the percentage
of peripheral blood CD4þ T lymphocytes was higher in
patients than in healthy donors (77±14% versus 36±8%,
respectively; Po0.01, unpaired t-test) and conversely, the
proportion of circulating CD3CD14þ monocytes was
reduced in patients (6±5% versus 15±7%; Po0.05,
unpaired t-test). In both physiological and pathological
conditions, IL-13Ra1 was expressed on peripheral blood
monocytes but not on lymphocytes (Figure 4). Thus, these
observations ruled out a potential effect of IL-13 on Se´zary
tumor cells. Cell surface expression of IL-13Ra1 was further
examined on normal immune cell subpopulations under
quiescent and stimulated conditions. The activation status of
CD4þ or CD8þ T lymphocytes, CD3CD14þ monocytes,
and CD14CD1aþ conventional or Langherans DCs was
monitored by the upregulation of CD69, IL-6 mRNA, and
P < 0.0001
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Figure 3. Correlation between MOR and IL-13 mRNA expression in lymph
node biopsies. (a) Relative IL-13 mRNA expression in lymph nodes expressing
(þ ) or not expressing () MOR. Lymph node specimens with detectable
MOR mRNA included five patients with Se´zary syndrome (K) and three
patients with follicular B-cell lymphoma (’). Data were analyzed by using
unpaired t-test. (b) Correlation between MOR and IL-13 mRNA expression
was calculated using a non-parametric Spearman correlation test (r¼0.94);
Po0.01. IL, interleukin; MOR, m-opioid receptor.
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Figure 4. Cytofluorometric analysis of IL-13Ra1 expression on peripheral monocytes and lymphocytes from healthy donors and patients with Se´zary
syndrome. Peripheral blood mononuclear cells, including CD14þCD3 monocytes (a and c) and CD3þCD4þ T lymphocytes (b and d) from healthy donors
(upper panels) and patients with Se´zary syndrome (lower panels) were examined for cell surface expression of IL-13Ra1. The figure depicts one representative
experiment for one healthy blood donor out of seven tested and for one patient with Se´zary syndrome out of four. CD, cluster of differentiation.
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CD86, respectively (Figure 5). Contrasting with monocytes,
IL-13Ra1 was not found on the surface of T lymphocytes,
conventional DCs and LCs in resting conditions. Surface
expression of IL-13Ra1 was unchanged upon activation
of lymphocytes (Figure 5a and b) and conventional DCs
(Figure 5d). However, activation of monocytes (Figure 5c)
and LCs (Figure 5e) resulted in an upregulation of IL-13Ra1.
The ability of IL-13 to upregulate MOR in IL-13Ra1-
expressing cells was then examined by adding IL-13 to cell
culture for 24 hours. Although IL-13 induced IL-13Ra1
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Figure 5. Cytofluorometric analysis of IL-13Ra1 expression on CD4þ and CD8þ T lymphocytes, conventional DCs, LCs, and monocytes from healthy
donors. IL-13Ra1 expression was investigated on naive and activated peripheral CD4þ (a) and CD8þ (b) T lymphocytes, on unstimulated and stimulated
CD14þCD3 monocytes (c) and on immature and mature monocyte-derived CD14CD1aþ conventional DCs (d) or LCs (e). In (a and b), PBMCs isolated from
healthy blood donors were activated (right panels) or not (left panels) by PHA for 24hours. Cell surface expression of IL-13Ra1 was examined by cytofluorometry
in the gated CD4þ (a) or CD8þ (b) T lymphocytes. Cell activation was checked by the expression of the inducible cell surface molecule CD69. In (c), monocytes
purified from healthy blood donors by anti-CD14 immuno-magnetic cell sorting were activated (right panels) or not (left panels) by incubating the cells with
LPS together with Poly(IC) for 48hours. Monocyte activation was testified by the increase in IL-6 mRNA as assessed by real-time quantitative PCR. Conventional
(d) and Langerhans (e) DCs were derived from monocytes in the presence of GM-CSF and IL-4 without (d) or with TGF-b (e), respectively. Cell activation
(left panels) induced by LPS plus Poly(IC) was assessed by the upregulation of CD86 cell surface expression. Results shown in the figure are representative of at least
three independent experiments. CD, cluster of differentiation; DC, dendritic cell; IL, interleukin; LC, Langerhans cell; LPS, lipopolysaccharide; PBMC, peripheral
blood mononuclear cell; PHA, phytohemagglutinin; Poly(IC), polyinosinic-polycytidylic acid; TGF-b, transforming growth factor-b.
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activation both in unstimulated and stimulated monocytes
as shown by upregulation of mannose receptor C type 1 and
down-modulation of IL-13Ra1 surface expression (data
not shown), MOR mRNA remained undetectable. By
contrast, IL-13 triggered MOR mRNA expression in activated
LCs as assessed by RT–PCR (Figure 6).
DISCUSSION
As shown in experiments comparing wild-type and MOR-
deficient mice, most of the immunosuppressive effects of
opioids are mediated by MOR (Gave´riaux-Ruff et al., 1998;
Wang et al., 2002a, b; Philippe et al., 2003). Some of these
immunomodulatory effects are dependent on stimulation of
MOR in situ (Yin et al., 2000; Mace et al., 2002; Wang et al.,
2002a, b). However, as exemplified in the T cell response to
mitogens, the inhibitory effect of morphine is dependent on
the tissue context. The administration of high doses of
morphine suppressed the proliferative response of T lympho-
cytes isolated from spleen but not from lymph nodes (Lysle
et al., 1993). In line with these observations, MOR expression
in immune lymph node cells, including DCs, macrophages,
and lymphocytes is dependent on cytokine environment
(Kraus et al., 2001, 2003a, b).
In this study, we found, as previously reported in human
peripheral blood mononuclear cells isolated from healthy
individuals (Gave´riaux et al., 1995), that DOR and KOR, but
not MOR, are expressed within normal tumor-free lymph
nodes. Whereas most of the lymph node biopsy samples from
patients with non-Hodgkin’s lymphomas did not express
MOR, all Se´zary syndrome lymph node samples expressed
the receptor. The recurrent expression of MOR was not due to
tumor cells colonizing the pathological lymph nodes as
assessed by RT–PCR, suggesting a role for the microenviron-
ment in the acquisition of MOR by surrounding normal
immune cells. The hypothesis that a cytokine-rich micro-
environment might contribute to upregulate MOR expression
in normal lymph node cells was supported by the
conjunction of two observations: (1) Se´zary syndrome is a
neoplastic disorder in which malignant T lymphocytes exhibit
a Th2 phenotype (Papadavid et al., 2003), (2) IL-4, the
prototypical Th2 cytokine, has been reported to induce MOR
mRNA synthesis in normal human blood T lymphocytes and
immune cell lines in vitro (Kraus et al., 2001). Comparison of
the Th2-related cytokine expression within lymph node
biopsy samples from patients with non-Hodgkin’s lympho-
mas revealed that the rate of IL-13 mRNA was significantly
higher in Se´zary syndrome. Several experimental observa-
tions argued for a contribution of IL-13 in MOR expression:
(1) IL-13 mRNA levels were higher within MOR-expressing
lymph nodes than in MOR-lacking lymph nodes, indepen-
dent of the type of lymphomas, (2) IL-13 and MOR mRNA
levels were correlated, and (3) The functional IL-13 receptor,
also known as the type II IL-4 receptor, is a heterodimer
constituted by the IL-4Ra chain and the IL-13Ra1 chain.
Thus, as a result of the common IL-4Ra chain of their
receptors, IL-4 and IL-13 cytokines may share many
biological activities (Hershey, 2003).
Surface expression of IL-13Ra1 was then examined on
immune cell subsets commonly present within pathological
lymph nodes from patients with primary cutaneous T-cell
lymphomas. Interleukin-13Ra1 was not found on the surface
of malignant CD4þ T lymphocytes and on normal CD4þ and
CD8þ T lymphocytes under quiescent or activated condi-
tions (Graber et al., 1998). The inability of IL-13 to stimulate
normal and neoplastic lymphocytes pointed out an IL-13-
mediated upregulation of MOR in surrounding normal
immune cells other than lymphocytes. In the absence of
Toll-like receptor-mediated stimulation, IL-13Ra1 was found
on monocytes but not on conventional DCs or LCs. Owing to
the low reactivity of LCs to Toll-like receptor 4 ligand (van
der Aar et al., 2007), we used a combination of lipopoly-
saccharide and polyinosinic-polycytidylic acid to stimulate
monocytes and both DC subsets. Although IL-13Ra1
remained undetectable in mature conventional DCs, the
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Figure 6. IL-13-induced MOR expression in IL-13Ra1-expressing immune cells. Freshly purified monocytes and monocyte-derived LCs stimulated with
LPS plus Poly(IC) were cultured in RPMI 1% FCS with (þ ) or without () 100 ng human rIL-13 for 24 hours. MOR mRNA expression was then examined
by RT–PCR as described in Figure 1. Results are representative of three independent experiments. IL-13Ra1 activation by IL-13 in monocytes was
evidenced by the increase in MRC1 mRNA as assessed by real-time quantitative PCR (right panels). Results are expressed as mean±SD of three
independent experiments performed in duplicates. CD, cluster of differentiation; FCS, fetal calf serum; IL, interleukin; LC, Langerhans cell; LPS,
lipopolysaccharide; PBMC, peripheral blood mononuclear cell; PHA, phytohemagglutinin; Poly(IC), polyinosinic-polycytidylic acid; MOR, m-opioid
receptor; MRC1, mannose receptor C type 1.
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increase in IL-13Ra1 on both LCs and monocytes after Toll-
like receptor -activation led us to consider them as two
potential targets for IL-13.
The capacity of IL-13 to induce MOR expression was
assessed on IL-13Ra1-expressing cells, including monocytes
and activated LCs. Interleukin-13-induced signaling is mainly
mediated through IL-4Ra chain (Hershey, 2003) and results in
the activation of signal transducer and activator of transcription
6 (STAT6) that has been reported to directly bind to MOR
promoter (Kraus et al., 2001). As shown, IL-4-responsive,
STAT6-binding sites might also mediate IL-13-induced MOR
transcription (Kraus et al., 2003a, b). However, we showed
that IL-13 does not upregulate MOR mRNAs in monocytes
within 24hours. Thus, IL-4-mediated MOR upregulation in
monocytes could be rather mediated through type I IL-4
receptor (IL-4Ra/common g-chain) complex, although we can
not formally rule out that an IL13-dependent MOR upregula-
tion in monocytes requires additional protein synthesis and
occurs later than 24hours (not investigated for technical
reasons). Response to IL-13 may differ between cell types. As
matter of fact, it has been reported that lipopolysaccharide-
induced tumor necrosis factor-a production was efficiently
inhibited in monocytes but not in macrophages (Hart et al.,
1999). Similarly, IL-13 triggered an increase in MOR mRNA
content in activated LCs but not in monocytes, whereas they
reacted to IL-13 by upregulating MRC1 (mannose receptor C
type 1) mRNA. Taken together, our data suggest that MOR
expression is dependent on IL-13, as well as subset and
activation status of DCs within lymph nodes.
Tumor microenvironment may generate permissive con-
ditions favoring neoplastic cell growth by inhibiting activa-
tion and/or effector phases of the immune response
(Rabinovich et al., 2007). Considering that MOR is the main
mediator of the immunosuppressive effects of opioids, our
results suggest that endogenous opioids produced within
Sezary lymph nodes might participate in the escape of
malignant cells from the immune response. Itching is a
feature of Se´zary syndrome. The physiopathological mechan-
isms of peripheral itching are not clearly understood but the
role of opioids is well accepted (Bigliardi et al., 2009). Thus,
an IL-13-rich environment might also favor an opioid-
mediated itching by upregulating MOR on cutaneous afferent
sensitive fibers in damaged skin.
MATERIALS AND METHODS
Biopsy specimens
Frozen lymph node biopsies from 39 patients with non-Hodgkin’s
lymphomas, including 11 patients with diffuse large cell lymphoma,
8 patients with follicular lymphoma, 8 patients with unspecified
peripheral T-cell lymphoma, 5 patients with Se´zary syndrome, and
7 patients with anaplastic large cell lymphoma were obtained from
our tissue bank (Department of Pathology, CHU Purpan, Toulouse,
France). Biopsies from nine tumor-free reactive lymph nodes were
also analyzed. According to the Declaration of Helsinki, a formal
consent was signed by all patients included in the study. Institutional
ethical approval was obtained in compliance with the Helsinki
agreement from ‘‘comite´ consultatif de protection des personnes et
des biens (CCPPB)’’ at the Purpan Hospital, Toulouse France.
Cytofluorometric analysis
Cells were incubated with optimal concentrations of antibodies for
30minutes at 4 1C in phosphate-buffered saline containing 5% fetal
calf serum, 5mM EDTA and 0.1% sodium azide. The mouse anti-
human monoclonal antibodies against surface antigens used were:
anti-CD3 (clone UCHT1), anti-CD4 (clone 13B8.2), anti-CD8 (clone
SFCI21Thy2D3), anti-CD14 (clone RMO52), anti-CD69 (clone
TP1.55.3) from Beckman Coulter (Fullerton, CA), anti-CD14 (clone
M5E2), anti-CD86 (clone 2331 (FUN-1)), anti-CD1a (clone HI149),
anti-E-Cadherin (clone 36/E-Cadherin) from BD PharMingen (BD
Biosciences, San Jose, CA) and anti-IL-13 receptor a1 chain (IL-
13Ra1; clone 419718; R&D systems, Minneapolis, MN). Data were
collected on 10,000 living cells by forward and side scatter intensity
on an Becton Dickinson LSR II flow cytometer and were
subsequently analyzed using the BD FACS Diva Software (Becton
Dickinson).
PCR analysis
Total RNA was isolated from tissue samples by guanidine isothiocyana-
te–phenol–chloroform extraction using ready-to-use TRIzol Reagent
(Invitrogen, Carlsbad, CA). The RNA was reverse-transcribed using
Moloney murine leukemia virus reverse transcriptase (Invitrogen) using
random hexamer oligonucleotides for priming. In negative controls, the
reverse transcriptase was replaced by H2O. complementary DNA
encoding for human MOR, DOR, KOR, CD158k, and hypoxanthine
phosphoribosyl transferase were amplified by PCR as previously
described (Jaume et al., 2004) using primers listed in Supplementary
Table S1 online. All the primer pairs used do not amplify genomic DNA.
The mRNAs encoding for IL-4, IL-5, IL-6, IL-10, IL-13, PENK,
MOR, and mannose receptor C type 1 were quantified by real-time
PCR. Primers were designed by using Primer Express Software
(Applied Biosystems, Foster City, CA; Supplementary Table S2). The
amplification was performed with an ABI Prism 7000 Sequence
Detector (Applied Biosystems) using the PCR SYBR Green sequence
detection system (Eurogentec, Seraing, Belgium). The PCR condi-
tions were: 2minutes at 50 1C, 10minutes at 95 1C followed by 40
cycles of two steps including denaturation: 15 seconds at 94 1C and
primer annealing/extension: 1minutes at 60 1C. Data were analyzed
using the software supplied with the Sequence Detector (Applied
Biosystems). The mRNA content was normalized to the metastatic
lymph node protein 51 (MLN51) mRNA and quantified relative to a
standard complementary DNA (calibrator sample) prepared from the
human Jurkat leukemia T cell line or the human monocytic cell line
U937 for cytokines, and from the human neuroblastoma cell lines
SH-SY5Y and SK-N-MC for MOR and PENK, respectively, using the
2DDC T method, where DDCT¼DCT sampleDCT calibrator. Gene ex-
pression in each sample was assessed in at least two independent
experiments run in duplicates. All the primer pairs used do not
amplify genomic DNA.
Cells and culture conditions
Peripheral blood mononuclear cells were prepared from freshly
heparinized blood samples or buffy coats by density gradient
centrifugation in Ficoll-Plaque (Amersham, GE Healthcare Life
Sciences, Little Chalfont, Buckinghamshire, UK). The CD14-expres-
sing monocytes were positively selected from peripheral blood
mononuclear cells by magnetic cell sorting using CD14 microbeads
(Miltenyi Biotec, Bergish Gladbach, Germany). Preparations of
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monocytes were more than 93% pure as assessed by cytofluoro-
metry. Conventional DCs were generated from monocytes in RPMI
10% fetal calf serum containing 100 ngml1 (1,000Uml1) of
human recombinant GM-CSF (PeproTech, Rocky Hill, NJ) and
50 ngml1 (250Uml1) of human recombinant IL-4 (PeproTech).
Langerhans cells were generated from monocytes by using GM-CSF,
IL-4, and 10 ngml1 (200Uml1) of human recombinant transform-
ing growth factor 1 (Geissmann et al., 1998). After 6 days of culture,
nonadherent cells were collected. Preparations were more than 90%
DC-enriched as assessed by cytofluorometry. Phenotype of LCs was
monitored by E-Cadherin upregulation as compared with conven-
tional DCs (Geissmann et al., 1998). T cells were nonspecifically
activated by adding 3 mgml1 phytohemagglutinin (Murex Diagnos-
tics Limited, Dartford, UK) for 24 hours. Activation of monocytes and
that of conventional DCs and LCs was induced by adding 1 mgml1
lipopolysaccharide together with polyinosinic-polycytidylic acid
(10 mg per 5 105 cells; Sigma, St Louis, MO) for 48 hours. For
cytokine stimulation, after washing with phosphate-buffered saline,
cells were cultured in RPMI 1% fetal calf serum (Kraus et al., 2001)
to reduce interference with growth factors or cytokines already
present in the serum.
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